Novel cell culture-adapted genotype 2a hepatitis C virus infectious clone

Journal of Virology

Volumn 86, Issue 19, 2012, Pages 10805-10820

  Date, Tomoko ^a   Kato, Takanobu ^a   Kato, Junko ^b   Takahashi, Hitoshi ^a   Morikawa, Kenichi ^a,c,g   Akazawa, Daisuke ^a,d   Murayama, Asako ^a   Tanaka Kaneko, Keiko ^a   Sata, Tetsutaro ^a,h   Tanaka, Yasuhito ^e   Mizokami, Masashi ^f   Wakita, Takaji ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b Tokyo Women s Medical University   (Japan)

^c SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TORAY INDUSTRIES INC   (Japan)

^e NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^f NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h TOYAMA INSTITUTE OF HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; ISOLEUCINE; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5A;

3' UNTRANSLATED REGION; AMINO ACID SEQUENCE; ARTICLE; CELL CULTURE; CLONE; CONTROLLED STUDY; GENE CONSTRUCT; GENE MAPPING; GENE SEQUENCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPLICON; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; VIRUS DETECTION; VIRUS GENOME; VIRUS ISOLATION; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; CELL CULTURE TECHNIQUES; CELL LINE; CLONING, MOLECULAR; DNA, COMPLEMENTARY; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; MALE; MICE; MICE, SCID; MIDDLE AGED; MUTATION; PHYLOGENY; SEQUENCE ANALYSIS, DNA; TIME FACTORS; TRANSFECTION;

HEPATITIS C VIRUS;

EID: 84867398704     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.07235-11     Document Type: Article

References (41)

1. Aizaki H, et al. 2008. Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection. J. Virol. 82:5715-5724.
2. Akazawa D, et al. 2007. CD81 expression is important for the permissive-ness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J. Virol. 81:5036-5045.
3. Akazawa D, et al. 2011. Production and characterization of HCV particles from serum-free culture. Vaccine 29:4821-4828.
4. Bartenschlager R, Lohmann V. 2000. Replication of hepatitis C virus. J. Gen. Virol. 81:1631-1648.
5. Bukh J, et al. 2002. Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpan-zees. Proc. Natl. Acad. Sci. U. S. A. 99:14416-14421.
6. Choo QL, et al. 1989. Isolation of a cDNA clone derived from a blood- borne non-A non-B viral hepatitis genome. Science 244:359-362.
7. Di Bisceglie AM, Hoofnagle JH. 2002. Optimal therapy of hepatitis C. Hepatology 36:S121-S127.
8. Enomoto N, et al. 1995. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J. Clin. Invest. 96:224-230.
9. Hiraga N, et al. 2011. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to inter-feron of hepatitis C virus. Hepatology 54:764-771.
10. Kato T, et al. 2008. Hepatitis C virus JFH-1 strain infection in chimpan- zees is associated with low pathogenicity and emergence of an adaptive mutation. Hepatology 48:732-740.
11. Kato T, et al. 2003. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125:1808-1817.
12. Kato T, et al. 2005. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. J. Clin. Microbiol. 43:5679-5684.
13. Kato T, et al. 2006. Cell culture and infection system for hepatitis C virus. Nat. Protoc. 1:2334-2339.
14. Kato T, et al. 2001. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J. Med. Virol. 64:334-339.
15. Kato T, et al. 2003. Processing of hepatitis C virus core protein is regu- lated by its C-terminal sequence. J. Med. Virol. 69:357-366.
16. Kiyosawa K, et al. 1990. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12:671-675.
17. Kohashi T, et al. 2006. Site-specific mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication. J. Vi-ral Hepat. 13:582-590.
18. Kolykhalov AA, et al. 1997. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277:570-574.
19. Kuo G, et al. 1989. An assay for circulating antibodies to a major etiologic virus of human non-A non-B hepatitis. Science 244:362-364.
20. Lindenbach BD, et al. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626.
21. Lindenbach BD, et al. 2006. Cell culture-grown hepatitis C virus is infec-tious in vivo and can be recultured in vitro. Proc. Natl. Acad. Sci. U. S. A. 103:3805-3809.
22. Lohmann V, et al. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
23. Maekawa S, et al. 2004. Introduction of NS5A mutations enables sub-genomic HCV replicon derived from chimpanzee-infectious HC-J4 iso-late to replicate efficiently in Huh-7 cells. J. Viral Hepat. 11:394-403.
24. McHutchison JG, et al. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1485-1492.
25. Merck & Co. 2011. Victrelis (boceprevir) prescribing information. Merck & Co., Whitehouse Station, NJ. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202258lbl.pdf.
26. Murayama A, et al. 2007. The NS3 helicase and NS5B-to-3=X regions are important for efficient hepatitis C virus strain JFH-1 replication in Huh7 cells. J. Virol. 81:8030-8040.
27. Murayama A, et al. 2010. RNA polymerase activity and specific RNA structure are required for efficient HCV replication in cultured cells. PLoS Pathog. 6:e1000885. doi:10.1371/journal.ppat.1000885.
28. Pietschmann T, et al. 2002. Persistent and transient replication of full- length hepatitis C virus genomes in cell culture. J. Virol. 76:4008-4021.
29. Pietschmann T, et al. 2009. Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing muta-tions. PLoS Pathog. 5:e1000475. doi:10.1371/journal.ppat.1000475.
30. Poynard T, et al. 1998. Randomised trial of interferon Universal-GreekwithMathPi.-1.H92512b plus ribavirin for 48 weeks or for 24 weeks versus interferon Universal-GreekwithMathPi.-1.H92512b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352:1426-1432.
31. Saeed M, et al. 2009. Evaluation of hepatitis C virus core antigen assays in detecting recombinant viral antigens of various genotypes. J. Clin. Micro-biol. 47:4141-4143.
32. Takahashi H, et al. 2010. Biological properties of purified recombinant HCV particles with an epitope-tagged envelope. Biochem. Biophys. Res. Commun. 395:565-571.
33. Tateno C, et al. 2004. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am. J. Pathol. 165:901-912.
34. U. S. Food and Drug Administration. 2011. FDA news release. FDA approves Incivek for hepatitis C. U.S. Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256299.htm.
35. U. S. Food and Drug Administration. 2011. FDA news release. FDA approves Victrelis for hepatitis C. U.S. Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm255390.htm.
36. Vertex Pharmaceuticals. 2011. Incivek (telaprevir) prescribing informa-tion. Vertex Pharmaceuticals, Cambridge, MA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201917lbl.pdf.
37. Wakita T. 2009. Isolation of JFH-1 strain and development of an HCV infection system. Methods Mol. Biol. 510:305-327.
38. Wakita T, et al. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
39. Yanagi M, Purcell RH, Emerson SU, Bukh J. 1997. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc. Natl. Acad. Sci. U. S. A. 94:8738-8743.
40. Yanagi M, Purcell RH, Emerson SU, Bukh J. 1999. Hepatitis C virus: an infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras. Virology 262:250-263.
41. Zhong JP, et al. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 102:9294-9299.